HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.
Stocks · News reference
CME Group, Weatherford International, RPM International And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 200 pts, CME Group shares rise on upbeat earnings. Super Micro Computer, Arrowhead Pharma, Phoenix Asia, Everforth also gain.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target
Reported Earlier, Arrowhead Reports Plozasiran Also Reduced Pancreatitis Risk In Severe Triglyceride Patients
Arrowhead Pharmaceuticals To Present Data On Plozasiran In Patients With Severe Hypertriglyceridemia At European Society Of Cardiology Congress
Shares of crypto-linked stocks are trading higher as Bitcoin prices hit $80,000 amid lower yields and a weaker dollar. Fed's Waller's comments that he is inclined to support holding interest rates steady may have further supported the speculative asset by easing concerns about tighter monetary policy and improving risk appetite.
Cango’s EcoHash Technology Completes Key Operational And Commercial Milestones For Its AI Compute Business
Cango Inc. (NYSE:CANG) ("Cango" or the "Company"), a leading Bitcoin miner leveraging its global operations to develop an integrated energy and AI compute platform, today announced that its